| A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma |
Ongoing |
Golcadomide / Rituximab |
3 |
CA0731003 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction |
Ongoing |
(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel |
3 |
ID-076A301 / SOS-AMI |
King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE) |
Ongoing |
Efanesoctocog alfa |
4 |
BIVV001005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4- related disease |
Ongoing |
Rilzabrutinib |
3 |
EFC17359 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| Immune Ablation Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation for The Treatment of Multiple Sclerosis: A Single-Arm Study |
Ongoing |
Busulfan BOS / Cyclophosphamide/ Thymoglobulin |
2 |
2251066 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR) |
Ongoing |
Vericiguat |
2 |
NCT0571408 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency (Harmony) |
Ongoing |
Pegtibatinase |
3 |
TVTX-TVT058-301 |
King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh) |
| DOMAIN Study: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region. |
Ongoing |
Acalabrutinib |
4 |
D8220R0008 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Real-World Effectiveness and Safety Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Sacituzumab Govitecan in Second Line and Beyond in Kingdom of Saudi Arabia. |
Ongoing |
Sacituzumab Govitecan |
4 |
GS-AE-979 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. |
Ongoing |
Frexalimab (SAR441344) |
3 |
EFC17504 |
King Saud University Medical City (Riyadh) |
